CPHI CHINA PHARMA HOLDINGS, INC.
Pharmaceutical Preparations · NYSE · SEC CIK 1106644 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.4%
TTM net income YoY-79.5%
TTM EPS YoY71.8%
Revenue 3-yr CAGR-17.9%
Net income 3-yr CAGR—
Margins
Gross margin14.2%
Operating margin-130.5%
Net margin-132.8%
FCF margin—
EBITDA margin-89.0%
Returns
ROE-24.2%
ROA-18.3%
ROIC (approx.)-20.5%
Asset turnover0.14x
Leverage & solvency
Liabilities / assets16.8%
Debt / equity0.00x
Current ratio0.77x
Interest coverage-157.66x
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.14M | $4.53M |
| Cost of revenue | $4.28M | $6.51M |
| Gross profit | -$131,950 | -$1.99M |
| R&D expense | $280,901 | $283,942 |
| SG&A expense | $2.45M | $1.78M |
| Operating income | -$3.24M | -$4.59M |
| Interest expense | $27,272 | $27,353 |
| Pretax income | -$3.19M | -$4.74M |
| Net income | -$3.19M | -$4.74M |
| EBITDA | -$1.74M | -$1.97M |
| EPS (basic) | -0.74 | -2.71 |
| EPS (diluted) | -0.74 | -2.71 |
| Balance sheet | ||
| Cash & equivalents | $345,112 | $626,879 |
| Receivables | $241,412 | $232,140 |
| Inventory | $1.62M | $2.27M |
| Current assets | $2.35M | $3.27M |
| PP&E, net | $4.39M | $4.88M |
| Intangibles | $24.08M | $6.70M |
| Total assets | $31.00M | $14.89M |
| Current liabilities | $7.40M | $5.02M |
| Short-term debt | $1.44M | $1.14M |
| Total liabilities | $8.26M | $7.14M |
| Shareholders' equity | $22.74M | $7.75M |
| Shares outstanding | 5.52M | 3.26M |
| Cash flow statement | ||
| Operating cash flow | $148,261 | -$406,063 |
| Capital expenditure | $59,324 | $38,411 |
| Free cash flow | $88,937 | -$444,474 |
| Investing cash flow | -$137,251 | -$291,718 |
| Financing cash flow | -$294,027 | -$33,782 |
| Depreciation & amortization | $1.50M | $2.62M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.